Persistent SARS-CoV-2 infection: significance and implications
HM Machkovech, AM Hahn, JG Wang… - The Lancet Infectious …, 2024 - thelancet.com
SARS-CoV-2 causes persistent infections in a subset of individuals, which is a major clinical
and public health problem that should be prioritised for further investigation for several …
and public health problem that should be prioritised for further investigation for several …
The Landscape of Antiviral Therapy for COVID-19 in the Era of Widespread Population Immunity and Omicron-Lineage Viruses
EA Meyerowitz, Y Li - Clinical Infectious Diseases, 2024 - academic.oup.com
The goals of coronavirus disease 2019 (COVID-19) antiviral therapy early in the pandemic
were to prevent severe disease, hospitalization, and death. As these outcomes have …
were to prevent severe disease, hospitalization, and death. As these outcomes have …
Synergistic Activity of Remdesivir–Nirmatrelvir Combination on a SARS-CoV-2 In Vitro Model and a Case Report
A Gidari, S Sabbatini, E Schiaroli, S Bastianelli… - Viruses, 2023 - mdpi.com
Background: This study aims to investigate the activity of the remdesivir–nirmatrelvir
combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …
combination against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and …
Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 Swab: a real-life study
Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-
2 in reducing the likelihood of disease progression and death. However, there are limited …
2 in reducing the likelihood of disease progression and death. However, there are limited …
Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients …
Summary Background Remdesivir (Veklury, Gilead Sciences, Foster City, CA, USA) and
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …
nirmatrelvir–ritonavir (Paxlovid, Pfizer, New York, NY, USA) were reported to improve the …
Real life experience on the use of Remdesivir in patients admitted to COVID-19 in two referral Italian hospital: a propensity score matched analysis
N Veronese, F Di Gennaro, L Frallonardo… - Scientific Reports, 2024 - nature.com
Remdesivir (RDV) was the first Food and Drug Administration (FDA)-approved medication
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …
for COVID-19, with discordant data on efficacy in reducing mortality risk and disease …
Optimizing COVID-19 treatment in immunocompromised patients: early combination therapy with remdesivir, nirmatrelvir/ritonavir and sotrovimab
I Gentile, M Foggia, M Silvitelli, A Sardanelli… - Virology Journal, 2023 - Springer
Background Morbidity and mortality are higher in immunocompromised patients affected by
COVID-19 than in the general population. Some authors have successfully used antiviral …
COVID-19 than in the general population. Some authors have successfully used antiviral …
[HTML][HTML] Antiviral combination therapies for persistent COVID-19 in immunocompromised patients.
After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls
upon immunocompromised patients who cannot mount endogenous immune response after …
upon immunocompromised patients who cannot mount endogenous immune response after …
Prevention and management of infectious complications in patients with chronic leucocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current …
M Mikulska, C Oltolini, E Zappulo, M Bartoletti… - Blood Reviews, 2024 - Elsevier
CLL is associated with an increased risk of infectious complications. Treatment with BTK or
BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections …
BCL-2 inhibitors does not seem to increase significantly the risk of opportunistic infections …
Executive summary of the consensus statement of the group for the study of infection in transplantation and other immunocompromised host (GESITRA-IC) of the …
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) arose in December 2019
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …
in China rapidly evolving to the Coronavirus Disease 2019 (COVID-19) pandemic. Since …